We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

Adcock Ingram, which counts Panado painkillers and the cold and flu product Corenza C among its brands, says an improvement in demand for over-the-counter (OTC) products and innovative marketing helped it grow trading profit by a quarter in its half year to end-December.

New products, such as additional Panado variants, helped boost Adcock’s consumer business to well above pre-pandemic levels, CEO Andy Hall told Business Day, with the group pleased by improved margins and about R200m in revenue from products that weren’t in the market a year ago...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now